Leber congenital amaurosis gene therapy - SalioGen Therapeutics
Alternative Names: LCA10-gene therapyLatest Information Update: 06 Sep 2024
At a glance
- Originator SalioGen Therapeutics
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Cep290 protein replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Leber congenital amaurosis
Most Recent Events
- 01 Aug 2024 Early research in Leber congenital amaurosis in USA (Parenteral) (SalioGen Therapeutics pipeline, August 2024)